DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes

Information source: AstraZeneca
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Type 2 Diabetes Mellitus

Intervention: exenatide and placebo (Drug); Exenatide and placebo (Drug); Exenatide and placebo (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: AstraZeneca

Official(s) and/or principal investigator(s):
James Malone, MD, Study Director, Affiliation: Eli Lilly and Company


As exenatide slows the rate at which materials leave the stomach, it is likely to alter the rate of intestinal absorption of oral drugs when administered within a certain timeframe relative to exenatide. In addition, the residence time within the stomach of other medication may be prolonged and data from this study will help assess the change in residence time in the presence of therapeutic doses of exenatide. This study will also evaluate the relationship between blood levels of exenatide and parameters measuring rate of stomach emptying.

Clinical Details

Official title: A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes

Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Primary outcome: To detect the mean difference in half gastric emptying time for a solid meal between any treatment and placebo


Minimum age: 25 Years. Maximum age: 75 Years. Gender(s): Both.


Inclusion Criteria:

- Subjects with at least 1 year history of type 2 diabetes mellitus.

- Subjects controlled by oral antidiabetic agents or diet and exercise demonstrated by

a screening HbA1c ≥7. 0% and ≤10. 0%.

- Between the body mass index (BMI) of 19 kg/m2 and 40 kg/m2, inclusive.

Exclusion Criteria:

- Within 4 months of the initial dose of study drug, have received a drug that has not

received regulatory approval for any indication.

- Persons who have previously completed or withdrawn from this study or any other study

investigating exenatide.

- Subjects who are using drugs that significantly affect gastrointestinal motility

(including acarbose, metoclopramide, and macrolide antibiotics).

- Subjects who intend to start new concomitant medication during the study, including

over-the counter medication, apart from occasional intake of paracetamol or vitamin/mineral supplements. Anti-emetic medication may be permitted at the investigator's discretion, except those that affect gastrointestinal motility.

- Subjects who have used insulin for more than 4 weeks within 3 months prior to


- Blood donation of more than 500 mL in the last 3 months of screening or any blood

donation within the last month.

Locations and Contacts

Research Site, Nottingham, United Kingdom
Additional Information

Starting date: January 2005
Last updated: February 20, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017